

Carboxypeptidase-Type Kininase of Human Kidney and Urine (40925)

DOBRIVOJE V. MARINKOVIC, PATRICK E. WARD, ERVIN G. ERDOS, AND
IVOR H. MILLS

Departments of Pharmacology and Internal Medicine, University of Texas Health Science Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas, and Department of Medicine, University of Cambridge Clinical School, Cambridge, England

Abstract. A carboxypeptidase was partially purified from human urine and a similar or identical enzyme was extracted from a particulate fraction of the human kidney. The enzyme cleaved basic C-terminal amino acids of peptides including bradykinin. The inhibition of the human renal/urinary carboxypeptidase was different from that of plasma carboxypeptidase N (kininase I) or pancreatic carboxypeptidase B. The urinary enzyme was not affected by inhibitors of catheptic enzymes or kininase II and has no carboxypeptidase A activity. The urinary/renal carboxypeptidase had a molecular weight of 40,000. The urinary carboxypeptidase did not cross-react with antiserum to human pancreatic carboxypeptidase B. These properties distinguish carboxypeptidase of human urine and kidney from plasma carboxypeptidase N and from pancreatic carboxypeptidase B.

Kinins are inactivated by various enzymes collectively called kininases (1, 2). Two of them, kininase I and II, cleave the C-terminal arginine and phenylalanyl-arginine of kinins, respectively. Kininase II also converts angiotensin I to angiotensin II. The major plasma kininase is kininase I (carboxypeptidase N; arginine carboxypeptidase, EC 3.4.17.3). Kininase II (dipeptidyl carboxypeptidase, EC 3.4.15.1) is concentrated mainly on the plasma membrane of endothelial and epithelial cells. Pancreatic carboxypeptidase B (EC 3.4.17.2) is also a potent inactivator of kinins by the release of C-terminal arginine (2).

Both bradykinin and kallidin are present in the urine (3-5) although kininase II, located on the brush border of the proximal tubules (6), eliminates plasma kinins that enter the nephron after glomerular filtration (7, 8). Thus kinins that appear in the urine are released intrarenally distal to the proximal tubules. Kinins alter sodium and water reabsorption (9) and release prostaglandins in the kidney (10, 11). Because of these effects of kinins, their inactivation in the kidney appears to be an important step in renal autoregulation. This consideration led us to study the properties of a carboxypeptidase-type kininase in human urine and kidney.

Materials and methods. Chemicals. The

substrates Bz-glycyl-argininic acid (hippuryl-argininic acid, HLAa), Bz-glycyl-arginine (HLA), Bz-glycyl-lysine (HLL), Ac-Phe-Arg, Ac-Ser-Pro-Phe-Arg, and bradykinin were purchased from Vega-Fox, Tucson, Ariz. Sephadex G-100, Sepharose 6B, and blue dextran 200 were obtained from Pharmacia, Uppsala, Sweden. DEAE-cellulose types 40 and 70 were from Carl Schleicher and Schuell Co., Kene, N.H.; CM-cellulose (type 32) was from Whatman, Balston, Ltd., England, and hydroxyapatite was from Bio-Rad, Richmond, Calif. The protein standards for molecular weight determination (such as ribonuclease, α -chymotrypsin, pepsin, ovalbumin, or bovine serum albumin) were purchased from Sigma Chemical Co., St. Louis, Mo. Other reagents were analytical grade. Teprotide (SQ 20881) was obtained from Dr. Z. Horovitz of Squibb Institute, Princeton, N.J.

Tissue preparations. Human kidneys were obtained from sudden death cadavers at the Department of Pathology and the Institute of Forensic Sciences, UTHSCD.

Normal human urine was collected from healthy adult volunteers. Kidneys were washed in cold isotonic saline and stored at -20° . After thawing, the tissue was ground twice in an electric grinder and homogenized at high speed for 60 sec in a

Waring blender in 50% (w/v) 0.25 M sucrose containing 0.1 M Tris-HCl buffer, pH 7.4. The homogenate was diluted with 1.5 vol of buffered sucrose and homogenized a second time for 60 sec. The homogenate was centrifuged (10,000g for 30 min) in a Sorvall refrigerated centrifuge. The supernatant was recentrifuged in a Beckman L2 or L5-65 ultracentrifuge (50,000g for 2 hr). The microsomal precipitate was quickly frozen to -40° . Subsequently it was homogenized in cold acetone for 30 sec in a Waring blender.

The acetone homogenate was immediately filtered in a Buchner funnel and the acetone powder was dried in a vacuum desiccator for 2 hr. The powder was then extracted overnight in 0.1 M phosphate buffer (5% w/v), pH 8.0, containing 20% glycerol and 10^{-4} M CoCl_2 .

Insoluble material was removed by centrifugation (5000g for 20 min) in a refrigerated Sorvall RC-2 centrifuge. The extract was then concentrated in the cold room with an Amicon PM-30 Diaflo membrane under nitrogen pressure.

Human blood samples were taken from healthy volunteers and the plasma was separated and lyophilized. All subsequent procedures with plasma were done in the same manner as the extraction of carboxypeptidase from the acetone powder of human kidney microsomes.

Human pancreatic carboxypeptidase B was purified to homogeneity as described previously (12).

Preparation of urinary enzyme. Twenty-five liters of human urine were concentrated 100-fold by ultrafiltration through a Diaflo type AM-10 membrane and dialyzed for 1 day against two changes of 2 liters of 0.05 M Tris-HCl buffer, pH 7.4, containing 10^{-4} M CoCl_2 .

DEAE-cellulose chromatography. The dialysate (225 ml) was added to a column (2 × 66 cm) of DEAE-cellulose. The column was washed with the buffer used above at a flow rate of 56 ml/hr and eluted with a stepwise-increased NaCl gradient. Urinary carboxypeptidase was eluted with 0.05 M NaCl. The active fraction was then concentrated to 100 ml by ultrafiltration and dialyzed against three changes of 2 liters of

0.01 M potassium phosphate buffer, pH 6.0.

Second DEAE-cellulose chromatography. The sample was applied to a column (2.2 × 28 cm) of DEAE-cellulose equilibrated with 0.01 M potassium phosphate buffer, pH 6.0. Carboxypeptidase was eluted with 0.075 M KCl, added to the same buffer at a flow rate of 30 ml/hr. After concentration to 5 ml by ultrafiltration, the sample was dialyzed against 0.05 M sodium acetate buffer, pH 7.2, containing 0.1 M NaCl.

Gel filtration. The active fraction was filtered on a column (2.5 × 95 cm) of Sephadex G-100 equilibrated with 0.05 M sodium acetate-acetic acid buffer, pH 7.2, containing 0.1 M NaCl. Eluent was collected in the same buffer in 3-ml fractions. The active fractions were combined and concentrated as above to 6 ml and dialyzed against 10^{-3} M potassium phosphate buffer, pH 6.5.

Hydroxyapatite column chromatography. The preparation obtained after gel filtration was passed through a column (2.2 × 10 cm) of hydroxyapatite. Carboxypeptidase was recovered only in the fraction that was not adsorbed on the column. The active fractions were combined, concentrated to 5 ml, and dialyzed against 0.005 M Tris-HCl buffer, pH 8.0.

Enzyme assay. The hydrolysis of HLA, HLL, Ac-Phe-Arg, and Ac-Ser-Pro-Phe-Arg was determined in a Beckman 121 automatic amino acid analyzer. The hydrolysis of HLAa was assayed in a uv spectrophotometer (13). The concentration of the substrates was 1×10^{-3} M. The inactivation of bradykinin was measured by bioassay on the isolated rat uterus (14, 15). In inhibition studies, the inhibitors were preincubated with the enzymes for 20 min at 37° before addition of substrate.

Molecular weight. For the determination of the molecular weight of carboxypeptidases from kidney, plasma, and urine, a column (2.5 × 100 cm) of Sepharose 6B was prepared in 0.05 M phosphate buffer, pH 6.8, containing 0.1 M NaCl. A 10-mg sample was applied to the column and eluted in 3-ml fractions with the equilibrating buffer at a flow rate of 21 ml/hr. The proteins used to standardize the column were: thyroglobulin (660,000), fibrinogen (380,000), γ

globulin (157,000), bovine albumin (68,000), ovalbumin (45,000), pancreatic carboxypeptidase B (35,000;12), and α -chymotrypsin (23,000).

The molecular weight of the partially purified urinary enzyme was also determined on a Sephadex G-100 column (2.5 \times 100 cm) which was equilibrated with 0.05 M Tris-HCl buffer, pH 7.4, containing 0.1 M NaCl. Fractions of 3 ml were collected at a flow rate of 15 ml/hr. The proteins used to standardize the column were bovine albumin (68,000), ovalbumin (45,000), pancreatic carboxypeptidase B (35,000;12), α -chymotrypsin (23,000), lysozyme (14,000), and ribonuclease (12,500). (Blue dextran V_t = 195 ml, bovine albumin V_t = 238 ml, ovalbumin V_t = 286 ml, pepsin V_t = 348 ml, and ribonuclease V_t = 461 ml.) The elution volume of the carboxypeptidase was determined (V_t = 312 ml) and the molecular weight was calculated from a standard profile of elution volume vs molecular weight.

Immunodiffusion. Antibody to human pancreatic carboxypeptidase B was elicited in rabbits. Qualitative immunoprecipitation was performed by Ouchterlony double-immunodiffusion analysis. Pancreatic and urinary carboxypeptidase were loaded separately onto agar gels. The center well of the plate contained rabbit antiserum elicited against human pancreatic carboxypeptidase B (12).

pH effect. The pH optimum of the urinary enzyme was studied by following the inactivation of bradykinin on the isolated

rat uterus in a phosphate buffer. The source of the enzyme was the carboxypeptidase obtained after the second DEAE-cellulose column chromatography.

Results. Purification. The partial purification of a carboxypeptidase-type kininase from human urine is summarized in Table I. The purification of the enzyme was followed by measuring the hydrolysis of HLAa after each step. The urinary enzyme was purified 283-fold from crude urine or 27-fold from urine concentrated by membrane filtration.

Substrate specificity. Table II compares the relative rates of hydrolysis of various substrates by human plasma carboxypeptidase N (16), kidney carboxypeptidase, urinary carboxypeptidase, and pancreatic carboxypeptidase B (17). The plasma, kidney, and urinary carboxypeptidases cleaved HLL faster than HLA. Pancreatic carboxypeptidase B acted the opposite way. Table II indicates that the renal enzyme hydrolyzed HLA and Ac-Phe-Arg relatively faster than the plasma enzyme, but urinary kininase hydrolyzed Ac-Ser-Pro-Phe-Arg and bradykinin more rapidly than either the plasma or the kidney enzyme. None of the preparations had any carboxypeptidase A-type activity since they did not cleave Bz-glycyl-phenylalanine.

Inhibition. Inhibition of the four human carboxypeptidases was studied with HLL as substrate (Table III). The compounds used inhibited plasma carboxypeptidase N

TABLE I. PURIFICATION OF CARBOXYPEPTIDASE FROM HUMAN URINE

Procedure	Total protein (mg)	Volume (ml)	Total units ^a	Units Per mg Protein ^b	Yield (%)	Purification
Membrane filtration	2025	225	112.5	0.055	100.0	1.0
DEAE-cellulose column chromatography (pH 7.7)	324	102	40.0	0.123	35.7	2.2
DEAE-cellulose (pH 6.0)	50	50	18.0	0.36	16.0	6.5
Sephadex G-100 filtration	20	20	10.0	0.5	8.9	9.0
Hydroxyapatite column chromatography	0.6	30	0.9	1.500	0.8	27.0

^a 1 unit = 1 nmol HLAa cleaved/min.

^b Crude urine = 0.0053.

TABLE II. RATIO OF HYDROLYSIS OF SUBSTRATES BY HUMAN CARBOXYPEPTIDASES

Substrate (10^{-3} M)	Source of enzyme			
	Plasma	Kidney	Urine	Pancreas
Bz-glycyl-lysine (HLL)	100	100	100	100
Bz-glycyl-arginine (HLA)	40	80	60	212
Ac-Phe-Arg ^a	18	80	55	—
Ac-Ser-Pro-Phe-Arg ^a	16	22	42	—
Bradykinin ^b	20	25	45	—
Bz-glycyl-phenylalanine	0	0	0	—

^a C-terminal fragment of kinins.

^b Determined by bioassay.

and pancreatic carboxypeptidase B differently than the renal or urinary carboxypeptidases. The inhibition of renal and urinary carboxypeptidases, however, was similar. EDTA and CdSO_4 inhibited pancreatic carboxypeptidase B (16, 17) less than the other three carboxypeptidases. ξ -Amino-*n*-caproic acid was effective only against the plasma enzyme (13, 16). Inhibitors of proteases, SH-enzymes and kininase II (DFP, *p*-chloromercuriphenyl sulfonic acid and teprotide), were ineffective.

Molecular weight. Figure 1 shows gel filtration of the plasma, renal, and urinary carboxypeptidases on a Sepharose 6B column. The elution volume of plasma carboxypeptidase N was similar to fibrinogen and indicated a molecular weight of approximately 280,000, in agreement with published data (2, 16). The elution volumes of both the renal and urinary carboxypeptidases indicated a molecular weight of

about 40,000. Similar results were obtained on a Sephadex G-100 column. The molecular weight of human pancreatic carboxypeptidase B was found to be 35,000, as previously established (12).

Effect of pH. The effect of pH on the inactivation of bradykinin by urinary carboxypeptidase was studied at pH 6, 7, and 8 in a 0.1 M phosphate buffer. The source of the enzyme was a partially purified fraction collected after the second DEAE-cellulose column chromatography step. (The enzyme was stable when stored at -20° for 14 months.) The inactivation of bradykinin, as measured on the isolated rat uterus, was maximal (100%) at pH 7. It was slightly slower at pH 8 (90%) and much slower at pH 6 (53%).

Immunodiffusion. The reaction of rabbit antiserum to purified human pancreatic carboxypeptidase B with human pancreatic and urinary carboxypeptidases in Ouch-

TABLE III. INHIBITION OF THE ACTIVITY OF HUMAN CARBOXYPEPTIDASES (%)

Inhibitor (M)	Source of Enzyme ^a			
	Plasma	Kidney	Urine	Pancreas
EDTA (2×10^{-3})	95	88	86	9
CdSO_4 (1.5×10^{-5})	80	77	82	31
ξ -Amino- <i>n</i> -caproic acid (1×10^{-2})	92	20	35	38
Argininic acid (5×10^{-4})	—	30	37	—
<i>p</i> -Chloromercuriphenyl sulfonic acid, DFP (10^{-3}) teprotide (SQ 20881; 10^{-4})	0	0	0	—

^a Substrate = Bz-glycyl-lysine.




FIG. 1. Gel filtration on a Sepharose 6B column of human plasma carboxypeptidase N (●—●), human renal carboxypeptidase (■—■), and human urinary carboxypeptidase (▲—▲). The estimated molecular weight of carboxypeptidase N is 280,000 and that of renal and urinary carboxypeptidase 40,000.

terlony double-immunodiffusion plates is shown in Fig. 2. The urinary carboxypeptidase did not cross-react with antiserum to pancreatic carboxypeptidase B, indicating that the two enzymes are antigenically different. In the control studies, pancreatic

carboxypeptidase formed a line of identity with the antiserum.

Discussion. The current upsurge of interest in urinary kallikrein excretion in various forms of hypertension (9, 18–20) stresses the importance of urinary kininases as regulators of locally acting kinins. If urinary kallikrein plays a role in the etiology of hypertension, it is probably through the kinin that it releases. Urine contains kinins (3–5) although plasma kinins normally do not appear in urine (7, 8) unless inactivating enzymes such as kininase II on the brush border of the proximal tubules (6) are inhibited (7). The kininase activity of urine was reported simultaneously with the discovery of urinary kinins (3). Later it was suggested that both kininase I and II-type enzymes are present in urine (14), but only kininase II or (angiotensin I-converting enzyme) has previously been purified from human urine (21).

We compared the properties of human carboxypeptidases which inactivate bradykinin by cleaving its C-terminal Arg. We found that human urine and kidney con-




FIG. 2. Human urinary carboxypeptidase does not cross-react with antiserum. Ouchterlony double-diffusion plates. Center well: rabbit antiserum to human pancreatic carboxypeptidase B. 1–4: 100–900 $\mu\text{g/ml}$ human urinary carboxypeptidase B; 5: 100 $\mu\text{g/ml}$ human pancreatic carboxypeptidase B.

tain a carboxypeptidase which is different from plasma carboxypeptidase N and pancreatic carboxypeptidase B. Plasma carboxypeptidase N (2, 13, 16, 22, 23) and pancreatic carboxypeptidase B (12, 17, 24) are well-characterized enzymes and the differences between the two enzymes are firmly established. The renal and the urinary enzymes have a much lower molecular weight than plasma carboxypeptidase N (40,000 vs 280,000). Plasma carboxypeptidase N (or kininase I) also differs from the urinary/renal carboxypeptidase in the ratio of the rates of hydrolysis of substrates and its sensitivity to inhibitors. For example, ξ -amino-*n*-caproic acid is effective only against plasma carboxypeptidase N.

Human pancreatic carboxypeptidase B has a molecular weight of about 35,000 (12), similar to that of the renal/urinary carboxypeptidase. Although injected porcine pancreatic carboxypeptidase B appears in the kidney and urine of laboratory animals (25), experiments with various substrates, inhibitors, and antisera to the pancreatic enzymes proved that the pancreatic and urinary/renal carboxypeptidases are also different.

The renal carboxypeptidase described here appears to be similar to the enzyme found in acetone-dried hog kidney powder (25) in that it cleaves C-terminal basic arginine faster if the penultimate amino acid is phenylalanine instead of glycine. Although there appear to be some differences between renal and urinary carboxypeptidases, for example, in the relative rates of hydrolysis of substrates, the two enzymes have many properties in common when compared to the plasma or pancreatic carboxypeptidases. Based on this, we hypothesize that the urinary kininase I-type enzyme originates in the kidney. A contribution of the low, 45,000 mol wt subunit of plasma carboxypeptidase N (16, 22, 23) to the kininase activity in urine, however, cannot be excluded.

The activity of urinary carboxypeptidase is lower at an acid pH; therefore below neutrality less urinary kinins are inactivated. The effect of the pH of tubular fluid on the release and inactivation of kinins will

be settled definitely only when the precise site of interaction of renal kallikrein with kininogen substrate is established.

The authors are grateful for the kind collaboration of Miss Martha Sheridan and Mrs. Katy Hammon in these experiments. P. E. Ward is an Established Investigator of the American Heart Association. This work was supported in part by NIH Grants HL 20494, HL 14187, and HL 16320, by a contract from the Department of the Navy (N00014-75-C-0807) and by the Texas Heart Association.

1. Erdős, E. G., Marinkovic, D. V., Ward, P. E., and Mills, I. H., *Fed. Proc.* **37**, 657 (1978).
2. Erdős, E. G., in "Handbook of Experimental Pharmacology" (E. G. Erdős, ed.), Supplement to Vol. XXV, p. 427. Springer, Heidelberg (1979).
3. Werle, E., and Erdős, E. G., *Arch. Exper. Path. Pharmacol.* **223**, 234 (1954).
4. Miwa, I., Erdős, E. G., and Seki, T., *Proc. Soc. Exp. Biol. Med.* **131**, 768 (1969).
5. Hial, V., Keiser, H. R., and Pisano, J. J., *Biochem. Pharmacol.* **25**, 2499 (1976).
6. Ward, P. E., Erdős, E. G., Gedney, C. D., Dowben, R. M., and Reynolds, R. C., *Biochem. J.* **157**, 643 (1976).
7. Nasjletti, A., Colina-Chourio, J., and McGiff, J. C., *Circ. Res.* **37**, 59 (1975).
8. Yoshinaga, K., Abe, K., Miwa, I., Furuyama, T., and Suzuki, C. H., *Experientia* **20**, 396 (1964).
9. Carretero, O. A., and Scicli, A. G., *Klin. Wochenschr.* **56**, Suppl. I, 113 (1978).
10. Terragno, N. A., Lonigro, A. J., Malik, K. U., and McGiff, J. C., *Experientia* **28**, 437 (1972).
11. Zusman, R. M., and Keiser, H. R., *J. Clin. Invest.* **60**, 215 (1977).
12. Marinkovic, D. V., Marinkovic, J. N., Robinson, C. J. G., and Erdős, E. G., *Biochem. J.* **163**, 253 (1977).
13. Erdős, E. G., and Yang, H. Y. T., in "Handbook of Experimental Pharmacology" (E. G. Erdős, ed.), Vol. XXV, p. 289. Springer, Heidelberg (1970).
14. Oshima, G., Gecse, A., and Erdős, E. G., *Biochim. Biophys. Acta* **350**, 26 (1974).
15. Trautschold, I., in "Handbook of Experimental Pharmacology" (E. G. Erdős, ed.), Vol. XXV, p. 52. Springer, Heidelberg (1970).
16. Osima, G., Kato, J., and Erdős, E. G., *Arch. Biochem. Biophys.* **170**, 132 (1975).
17. Folk, J. E., Piez, K. A., Carroll, W. R., and Gladner, J. A., *J. Biol. Chem.* **235**, 2272 (1960).
18. Margolius, H. S., Geller, R. G., de Jong, W., Pisano, J. J., and Sjoerdsma, A., *Circ. Res.* **30-31**, 125 (1972).

19. Mills, I. H., in "Handbook of Experimental Pharmacology" (E. G. Erdős, ed.), Supplement to Vol. XXV, p. 549. Springer, Heidelberg (1979).
 20. Ward, P. E., and Margolius, H. S., in "Handbook of Experimental Pharmacology" (E. G. Erdős, ed.), Supplement to Vol. XXV, p. 526. Springer, Heidelberg (1979).
 21. Kokubu, T., Kato, I., Nishimura, K., Yoshida, N., Hiwada, K., and Ueda, E., *Clin. Chim. Acta* **89**, 375 (1978).
 22. Jeanneret, L., Roth, M., and Bargetzi, J. P., H.S., *Z. Physiol. Chem.* **357**, 867 (1976).
 23. Plummer, T. H., and Hurwitz, M. Y., *J. Biol. Chem.* **253**, 3907 (1978).
 24. Geokas, M. D., Largman, C., Brodrick, J. W., Raeburn, S., and Rinderknecht, H., *Biochim. Biophys. Acta* **391**, 396 (1975).
 25. Erdős, E. G., and Yang, H. Y. T., in "Hypotensive Peptides" (E. G. Erdős, N. Back, and F. Sicuteri, eds.), p. 235. Springer, New York (1966).
 26. Ward, P. E., and Erdős, E. G., in "Kininogenases Kallikrein" (G. L. Haberland, J. W. Rohen, and T. Suzuki, eds.), Vol. 4, p. 107. Schattauer, Stuttgart (1977).
-

Received November 5, 1979. P.S.E.B.M. 1980, Vol. 165.